DUBLIN–(BUSINESS WIRE)–The “Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This ‘Acute-On-Chronic Liver Failure (ACLF)-Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Acute-on-chronic liver failure (ACLF) Epidemiology
The epidemiology division’s Acute-on-chronic liver failure (ACLF) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Country Wise- Acute-on-chronic liver failure (ACLF) Epidemiology
The epidemiology segment also provides the Acute-on-chronic liver failure (ACLF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM cases of Acute-on-chronic liver failure (ACLF) were 61,026 in 2020.
Acute-on-chronic liver failure (ACLF) Drug Chapters
The drug chapter segment of the Acute-on-chronic liver failure (ACLF) report encloses the detailed analysis of ACLF marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Acute-on-chronic liver failure (ACLF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Currently, there is no specific effective treatment available for patients with ACLF, and therefore treatment is based on organ support and treatment of associated complications. When ACLF is associated with a precipitating factor (i.e., bacterial infections, GI bleeding, alcoholism, and drug toxicity), early identification and treatment of the precipitating factor are essential.
However, this may not prevent the development or the worsening of the syndrome. In addition, in up to 40% of patients, a precipitating factor may not be identified. Moreover, available data suggest that although the precipitating factor may be the trigger of ACLF, it may not be an essential predictor of prognosis.
Acute-On-Chronic Liver Failure (ACLF) Emerging Drugs
Grifols Therapeutics evaluates the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products, and toxins. Other physiological functions include antioxidant properties, free radical scavenging, and capillary membrane integrity.
Acute-On-Chronic Liver Failure (ACLF) Market Outlook
The Acute-On-Chronic Liver Failure (ACLF) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Acute-On-Chronic Liver Failure (ACLF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Acute-On-Chronic Liver Failure (ACLF) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Acute-On-Chronic Liver Failure (ACLF) market in 7MM is expected to change in the study period 2018-2030.
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 ACLF Epidemiology Overview at a Glance
3.1 Patient Share Distribution of ACLF in 2018
3.2 Patient Share Distribution of ACLF in 2030
4 ACLF Market Overview at a Glance
4.1 Market Share (%) Distribution of ACLF in 2018
4.2 Market Share (%) Distribution of ACLF in 2030
5 Executive Summary of Acute on Chronic Liver Failure
6 Organizations
7 SWOT Analysis of Acute-on-Chronic Liver Failure
8 Disease Background and Overview
8.1 Introduction
8.2 Heterogeneity of definitions
8.3 Types of ACLF
8.4 Clinical characteristics and pathophysiology
8.5 Diagnosis of ACLF
8.6 ACLF Biomarkers
9 Country-wise Epidemiology of Acute-on-Chronic Liver Failure (ACLF)
9.1 Assumptions and Rationale: 7MM
10 Epidemiology and Patient Population
10.1 Key Findings
10.2 7MM Total Prevalent Patient Population of Acute-on-chronic liver failure
10.3 United States
10.3.1 Cases of Acute-on-chronic liver failure (ACLF) in the United States
10.3.2 Cases of ACLF by Grades in the United States
10.3.3 Organ failures associated with ACLF in the United States
10.3.4 Potential precipitating events of ACLF in the United States
10.4 Germany
10.5 France
10.6 Italy
10.7 Spain
10.8 United Kingdom
10.9 Japan
11 Treatment
11.1 Guidelines
11.1.1 APASL
11.1.2 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
11.2 Case Study
11.2.1 Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis
11.3 Patient Journey
12 Unmet Needs
13 Emerging Therapies
13.1 Albutein (PE-A 5%): Grifols Therapeutics
13.2 HepaStem: Promethera Biosciences
14 Other Promising Candidates
14.1 Nitazoxanide (NTZ): GENFIT
14.2 TAK-242: Akaza Bioscience
14.3 APZ2: RHEACELL
14.4 VS-01: Versantis
15 Suspended Products
15.1 Livantra: Martin Pharmaceuticals
16 Acute-on-chronic liver failure (ACLF): 7 Major Market Analysis
16.1 Key Findings
15.1 Market Size of Acute-on-chronic liver failure in 7MM
16.2 Market Outlook: 7MM
17 Country-wise Market Analysis: Acute-on-chronic liver failure (ACLF)
15.2 United States
15.2.1 Total Market size of Acute-on-chronic liver failure
15.2.2 Acute-on-chronic liver failure Market Size by Therapies
15.3 EU5 Countries
15.3.1 Germany
17.1.1 France
17.1.2 Italy
17.1.3 Spain
17.1.4 United Kingdom
17.2 Japan
Companies Mentioned
- Grifols Therapeutics
- Promethera Biosciences
- GENFIT
- Akaza Bioscience
- RHEACELL
- Versantis
- Martin Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/x5ievt
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900